Shots:
- The US FDA approved Awiqli (insulin icodec-abae; 700 units/mL) to improve glycaemic control in adults with type 2 diabetes as an adjunct to diet & exercise, with Novo planning a US launch in the FlexTouch device in H2’26
- Approval was based on the P-IIIa (ONWARDS) program assessing Awiqli (QW) vs basal insulin (QD) in four treat-to-target trials (~2,680 adults with uncontrolled T2D), used with mealtime insulin or oral anti-diabetic agents &/or GLP-1 receptor agonists
- The trials showed HbA1c reduction, with a safety profile of Awiqli consistent with the daily basal insulin class
Ref: Novo Nordisk | Image: Novo Nordisk | Press Release
Related News: The United Laboratories and Novo Nordisk Report P-II Trial Data on UBT251 in Chinese Patients with Type 2 Diabetes
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
